10
Jan

2018

GliaCure Highlighted in ADDF Annual Report

GliaCure’s compound GC021109 and its successful Phase 1 clinical trial were highlighted in the Alzheimer’s Drug Discovery Foundation (ADDF) Annual Report, issued in late 2017. The report points out that there is growing research to suggest that anti-inflammatory approaches may hold the key to treating the underlying causes of Alzheimer’s disease, and shows that GC021109…more »

23
Feb

2017

Prevention, Not Cure, as a Way Forward in Alzheimer’s Disease

Many of us have read with dismay of recent clinical trial failures in Alzheimer’s disease. Are researchers and pharma companies wrong in considering amyloid as a target for therapies? Not necessarily. As a recent cover article in Newsweek points out, the problem with many of these trials may not be the target but the point…more »

16
Dec

2015

GliaCure Completes Successful Proof of Concept Phase 1b Clinical Trial in Alzheimer’s Disease

GliaCure, a privately-held biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glial targets, announced yesterday that it has successfully completed a Phase 1b clinical trial of its lead product candidate, GC021109, a compound developed as a disease-modifying treatment for Alzheimer’s disease. The trial, which began in February 2015,…more »

24
Jul

2015

Mixed results in Alzheimer’s trials but continued enthusiasm for the amyloid hypothesis and the development of treatments

At the Alzheimer’s Association International Conference (AAIC) this week in Washington DC, Biogen and Eli Lilly presented results from their latest Alzheimer’s disease clinical trials. Biogen caused a great deal of excitement earlier this year when they released data from a Phase 1b clinical trial using an antibody to remove amyloid from the brain (see…more »

23
Mar

2015

Biogen success heralds new enthusiasm for investments in Alzheimer’s disease clinical trials

On March 17, 2015 Biogen reported interim results of its recent clinical trial using an antibody to treat Alzheimer’s disease. These results were extremely encouraging as they demonstrated both significant reductions in amyloid and improvements in cognition in patients with Alzheimer’s disease.  This success is certain to stimulate new enthusiasm for investing in clinical trials…more »

17
Mar

2015

GliaCure Receives $1 Million Grant for Phase 1b Alzheimer’s Clinical Trial

Glia-based approach to Alzheimer’s disease provides a novel opportunity for treatment GliaCure, a biotechnology company developing innovative therapies based on glial targets, announced today that it has been awarded a $1 million grant by the Alzheimer’s Drug Discovery Foundation (ADDF) to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease.…more »

18
Sep

2014

Signs of optimism for neurodegeneration research

On Monday, September 8th 2014 I had the pleasure of meeting several GliaCure investors at our annual shareholders’ meeting. In addition to dealing with the normal business of this meeting we were able to update the shareholders on our latest progress and on our timeline for plans for 2015. I am always thrilled by the excitement of…more »

16
Aug

2014

GliaCure Appoints New Member to Board of Directors

Mr. Zakrzewski is a Seasoned Life Sciences Leader  GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, announced today that it has appointed Joseph S. Zakrzewski to the Company’s Board of Directors.  Mr. Zakrewski brings more than 20 years of experience to his new role as…more »

26
Feb

2014

Glia and ALS

On February 10, 2014 the ALZFORUM (www.alzforum.org) highlighted work by a team from Columbia University showing that astrocytes, a specialized type of glia cell, cause the death of motor neurons in an in vitro study of cells from ALS patients. The authors of the study are now trying to identify the toxic factor that astrocytes…more »

05
Sep

2013

Glia’s role in schizophrenia

A group from the Netherlands has recently reported on a likely role for glia in schizophrenia susceptibility. Based on studies that glial cells play a significant role in synaptic transmission the group carried out a a functional gene set analysis to test for the combined effects of genetic variants in glial type-specific genes for association with…more »

Page 1 of 2